On the 25th of April, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave Givinostat (Duvyzat) a …
European Medicines Agency Issues Positive Opinion on GivinostatRead More
Capricor Therapeutics Reports Positive Long-Term Results for Deramiocel in Treating Duchenne Muscular Dystrophy
This week Capricor Therapeutics announced positive long-term data from its' ongoing HOPE-2 open-label extension (OLE) clinical trial, highlighting the …
Edgewise announces FDA authorisation for Phase 2 clinical trial
Edgewise has announced the FDA has authorized Phase 2 clinical trial for the treatment of Duchenne. The Lynx trial is a placebo-controlled trial to …
Edgewise announces FDA authorisation for Phase 2 clinical trialRead More
Results from Italfarmaco’s EPIDYS trial
Italfarmaco Group announces positive topline data from Phase 3 trial showing beneficial effect of Givinostat in patients with Duchenne muscular …
Edgewise-funded natural history trial of Becker Muscular Dystrophy (BMD) now enrolling
Edgewise Therapeutics has announced the start of an observational trial in participants with Becker Muscular Dystrophy (‘BMD’)) as assessed by …
Edgewise-funded natural history trial of Becker Muscular Dystrophy (BMD) now enrollingRead More
Duchenne Science events back on the road in 2020
We've welcomed over 100 people to our Science on Tour events throughout 2019, these empowering and invaluable sessions have been a huge success and we …
